Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 15,129 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Randomized Controlled Study Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Peri-menopausal and Menopausal Women With Thinning Hair

NCT04048031
View directory record Official record
Conditions
Hair Thinning
Interventions
Nutrafol Supplement Capsules, Placebo Capsules
Dietary Supplement · Other
Lead sponsor
Ablon Skin Institute Research Center
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Manhattan Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 23, 2026, 9:46 PM EDT
Completed Not applicable Interventional Results available

Vivaer® Procedure for Treatment of Nasal Airway Obstruction Study

NCT04549545
View directory record Official record
Conditions
Nasal Airway Obstruction
Interventions
Vivaer ARC Stylus, Sham
Device
Lead sponsor
Aerin Medical
Industry
Eligibility
18 Years to 85 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
12
States / cities
Roseville, California • Torrance, California • Coral Springs, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 23, 2026, 9:46 PM EDT
Completed Not applicable Interventional

Exercise in Peritoneal Dialysis Patients (PDEX)

NCT03980795
View directory record Official record
Conditions
Peritoneal Dialysis, Kidney Failure, Chronic
Interventions
Exercise Program
Other
Lead sponsor
Satellite Healthcare
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 23, 2026, 9:46 PM EDT
Completed Phase 2 Interventional

An Effectiveness And Safety Study Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis

NCT00739739
View directory record Official record
Conditions
Interstitial Cystitis, Painful Bladder Syndrome
Interventions
PD 0299685 at 15mg BID, PD 0299685 at 30mg BID, placebo for PD 0299685
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
23
States / cities
Mobile, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Oct 23, 2026, 9:46 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial

NCT05083312
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet
Drug
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
12 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Indianapolis, Indiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 23, 2026, 9:46 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of 4975 in Patients Undergoing Total Knee Replacement

NCT00681356
View directory record Official record
Conditions
Total Knee Arthroplasty (Replacement)
Interventions
4975, 15 and 5 mg, Placebo Comparator, 4975 - 5 mg
Drug
Lead sponsor
Anesiva, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
25
States / cities
Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 20 more
Source: ClinicalTrials.gov public record
Updated May 4, 2009 · Synced Oct 23, 2026, 9:46 PM EDT
Completed Phase 3 Interventional Results available

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

NCT05952856
View directory record Official record
Conditions
Hypercholesterolemia, Familial Hypercholesterolemia
Interventions
Enlicitide Decanoate, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
2,912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
49
States / cities
Daphne, Alabama • Foley, Alabama • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 9:46 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Study to Assess Droxidopa in the Treatment of Freezing Of Gait Symptoms in Patients With Parkinson's Disease

NCT01331122
View directory record Official record
Conditions
Gait Disorders, Neurologic
Interventions
droxidopa
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
30 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
West Bloomfield, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 23, 2026, 9:46 PM EDT
Completed Phase 2 Interventional

A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00391729
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
ABT-089, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 60 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
23
States / cities
Mesa, Arizona • Lafayette, California • Oceanside, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2011 · Synced Oct 23, 2026, 9:46 PM EDT
Terminated Phase 4 Interventional Results available

Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.

NCT04877457
View directory record Official record
Conditions
Radiologically Isolated Syndrome, Multiple Sclerosis
Interventions
Ocrelizumab, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
North Haven, Connecticut • New York, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 23, 2026, 9:46 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study of the Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of IV Acetaminophen for the Treatment of Acute Pain in Pediatric Patients

NCT01635101
View directory record Official record
Conditions
Acute Pain
Interventions
IV Acetaminophen, IV Control
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
1 Day to 2 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
22
States / cities
Birmingham, Alabama • Orange, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 23, 2026, 9:46 PM EDT
Completed Phase 2 Interventional Results available

A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

NCT02109172
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD
Interventions
TD-4208, Placebo
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
40 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 23, 2026, 9:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease

NCT05370495
View directory record Official record
Conditions
Dry Eye Disease
Interventions
SY-201 Ophthalmic Solution 2.0%, SY-201 Ophthalmic Solution 1.0%, SY-201 Ophthalmic Solution 0.5%, SY-201 Ophthalmic Solution Vehicle
Drug
Lead sponsor
Seinda Pharmaceutical Guangzhou Corporation
Industry
Eligibility
18 Years to 99 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 23, 2026, 9:46 PM EDT
Recruiting Phase 2 Interventional

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

NCT07405801
View directory record Official record
Conditions
Breast Cancer
Interventions
Inavolisib, Ribociclib, Fulvestrant, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
10
States / cities
Anaheim, California • Palo Alto, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 9:46 PM EDT
Completed Phase 2Phase 3 Interventional

ADCC Mediated B-Cell dEpletion and BAFF-R Blockade

NCT03217422
View directory record Official record
Conditions
Autoimmune Hepatitis
Interventions
VAY736, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
Coronado, California • Rialto, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 23, 2026, 9:46 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)

NCT00509145
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Laquinimod, Placebo
Drug · Other
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
23
States / cities
Phoenix, Arizona • Centennial, Colorado • Fort Collins, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 23, 2026, 9:46 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac Disease

NCT03738475
View directory record Official record
Conditions
Celiac Disease
Interventions
TIMP-GLIA, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
8
States / cities
Jacksonville, Florida • Meridian, Idaho • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 23, 2026, 9:46 PM EDT
Completed Phase 1 Interventional Results available

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer

NCT03343301
View directory record Official record
Conditions
Gastrointestinal Cancer, Gastrointestinal Cancer Metastatic, Gastric Cancer
Interventions
Bemarituzumab, Modified FOLFOX6
Biological · Drug
Lead sponsor
Five Prime Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Tucson, Arizona • Greenbrae, California • Whittier, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 23, 2026, 9:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730

NCT03054194
View directory record Official record
Conditions
Healthy Participants
Interventions
E2730, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 23, 2026, 9:46 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

NCT00797966
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
OPC-34712, Placebo, ADT
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
50
States / cities
Arcadia, California • Beverly Hills, California • Escondido, California + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 23, 2026, 9:46 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults

NCT04723394
View directory record Official record
Conditions
COVID-19
Interventions
AZD7442, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
24
States / cities
Jasper, Alabama • Tucson, Arizona • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 23, 2026, 9:46 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Nutritional Supplement Lumenato and Its Impact on Skin Parameters in Healthy Female Subjects

NCT04356456
View directory record Official record
Conditions
Skin
Interventions
Lumenato
Dietary Supplement
Lead sponsor
LycoRed Ltd.
Industry
Eligibility
35 Years to 55 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 23, 2026, 9:46 PM EDT
Terminated Phase 2 Interventional Results available

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

NCT03840902
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
M7824, Placebo, Durvalumab, Etoposide, Pemetrexed, Carboplatin, Paclitaxel, Cisplatin, Intensity Modulated Radiation Therapy (IMRT)
Drug · Radiation
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
21
States / cities
Orange, California • Santa Monica, California • Colorado Springs, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 23, 2026, 9:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of IXT-m200

NCT05027451
View directory record Official record
Conditions
Healthy
Interventions
IXT-m200, Placebo
Drug · Other
Lead sponsor
InterveXion Therapeutics, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 23, 2026, 9:46 PM EDT